Evidence item

The primary AMP-trial analysis reports de novo escape mutations in 8 of 26 VRC01-treated participants and none in 21 placebo participants. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 20148

Source: Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials · locator {} · excerpt hash sha256:ea25bbd932d89fef9f1563b9f48291ef7326f745f34080e4c45c4751837ce12e

Here we analysed 11,730 HIV envelope sequences generated during the AMP trials from 47 participants, identifying VRC01-mediated de novo escape mutations in 8 of 26 VRC01-treated participants but none in 21 placebo participants.